Cavitation Technologies, Inc. (CVAT) Form 10-Q — Oct 27, 2026
Cavitation Technologies filed its fiscal Q1 2027 10-Q showing zero revenue, a $208,000 net loss, and just $94,000 in cash against a $739,000 stockholders' deficit, with management stating existing cash will not sustain operations for the next twelve months. Both management and its auditor have raised substantial doubt about the company's ability to continue as a going concern. The headline event is a pending tender offer from BrightFlixx Finance Luxembourg S.A. to acquire all outstanding shares for an aggregate $35 million in cash less liabilities, signed October 9, 2026 and replacing a terminated EGS agreement.
Key figures
- Eps
- 0
- Revenue
- 0
- Total Debt
- 707000
- Total Assets
- 118000
- Cash Position
- 94000
- Deal Value Usd
- 35000000
- Shares Outstanding
- 324320459
- Shares sold at
- 0.03
- Warrants outstanding
- 14269400
- Q1 revenue prior year
- 3000
- Unregistered equity raise
- 140000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.